RNase Protection Assay
EMSA,凝胶阻滞实验技术文献,以及很好protocol,troubleshooting
Aromatic Hydrocarbon Receptor(AhR)⅐AhR NuclearTranslocator-and p53-mediated Induction of theMurine Multidrug Resistance mdr1Gene by3-Methylcholanthrene and Benzo(a)pyrene in Hepatoma Cells*Received for publication,September18,2000,and in revised form,November10,2000Published,JBC Papers in Press,November28,2000,DOI10.1074/jbc.M008495200Marie-Claude Mathieu,Isabelle Lapierre,Karine Brault‡,and Martine Raymond§From the Institut de Recherches Cliniques de Montre´al,Montre´al,Que´bec H2W1R7,CanadaThe mouse multidrug resistance gene family consists of three genes(mdr1,mdr2,and mdr3)encoding P-gly-coprotein.We show that the expression of mdr1is in-creased at the transcriptional level upon treatment of the hepatoma cell line Hepa-1c1c7with the polycyclic aromatic hydrocarbon3-methylcholanthrene(3-MC). This increase is not observed in the aromatic hydrocar-bon receptor(AhR)-defective TAOc1BP r c1and the AhR nuclear translocator(Arnt)-defective BP r c1variants, demonstrating that the induction of mdr1by3-MC re-quires AhR⅐Arnt.We show that the mdr1promoter (؊1165to؉84)is able to activate the expression of a reporter gene in response to3-MC in Hepa-1c1c7but not in BP r c1cells.Deletion analysis indicated that the re-gion from؊245to؊141contains cis-acting sequences mediating the induction,including a potential p53bind-ing sequence.3-MC treatment of the cells increased the levels of p53and induced p53binding to the mdr1pro-moter in an AhR⅐Arnt-dependent manner.Mutations in the p53binding site abrogated induction of mdr1by 3-MC,indicating that p53binding to the mdr1promoter is essential for the induction.Benzo(a)pyrene,a polycy-clic aromatic hydrocarbon and AhR ligand,which,like 3-MC,is oxidized by metabolizing enzymes regulated by AhR⅐Arnt,also activated p53and induced mdr1tran-scription.2,3,7,8-Tetrachlorodibenzo-p-dioxin,an AhR ligand resistant to metabolic breakdown,had no effect. These results indicate that the transcriptional induc-tion of mdr1by3-MC and benzo(a)pyrene is directly mediated by p53but that the metabolic activation of these compounds into reactive species is necessary to trigger p53activation.The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1independently of AhR⅐Arnt further supports the proposition that mdr1is transcriptionally up-regulated by p53in response to DNA damage.Multidrug resistance(MDR)1is characterized by cross-resis-tance of the cells to a large number of structurally and func-tionally unrelated cytotoxic agents used in chemotherapy.In cultured cells,MDR is frequently caused by the overexpression of P-glycoprotein(Pgp),an integral membrane protein belong-ing to the ATP-binding cassette superfamily of transporters and which functions as an energy-dependent efflux pump of cytotoxic drugs(1,2).Pgp is encoded by a small family of genes with two members in humans(MDR1and MDR2/MDR3)and three in rodents(mdr1/mdr1b,mdr2,and mdr3/mdr1a)(1,2). Only one human gene(MDR1)and two rodent genes(mdr1/ mdr1b and mdr3/mdr1a)can confer MDR upon overexpression in drug-sensitive cells(1,2).The different mdr genes and Pgp isoforms are expressed in a tissue-specific manner(1,2).In the mouse,mdr1is expressed mostly in the adrenal cortex,kidney,and pregnant uterus, mdr2in the liver at the canalicular face,and mdr3in the intestine and to a lesser extent in the heart,liver,lung,and capillaries of the brain(3).Pgps are localized on the apical membrane of epithelial cells lining luminal spaces,suggesting that they function in normal tissues as transporters of toxic substances and/or specific endogenous cellular products(4). Knockout mice experiments have demonstrated a role for the mdr3gene in the maintenance of the blood-brain barrier and drug elimination and for the mdr2gene in the transport of phospholipids in the bile(5,6).No physiological function has been attributed to the mouse mdr1gene so far,since knockout mdr1(Ϫ/Ϫ)mice display no obvious physiological abnormali-ties(7).However,different experimental evidence indicates that Pgp encoded by mdr1can serve in the transport of steroids(8).A number of factors have been found to modulate the level of mdr gene expression in the liver.For example,high levels of MDR1RNA have been found in human hepatocarcinomas,and overexpression of the mdr1isoforms has also been observed in rodent liver during cholestasis,during regeneration following partial hepatectomy,during chemically induced hepatocarcino-genesis,and following administration of various natural and synthetic xenobiotics(1,2).In particular,it has been shown that expression of the rat mdr1b gene is increased in liver cells in response to treatment with various polycyclic aromatic hy-*This work was supported by a research grant from the Cancer Research Society Inc.(to M.R).The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked“advertisement”in accordance with18 U.S.C.Section1734solely to indicate this fact.‡Supported by a studentship from the Medical Research Council ofCanada.Present address:Dept.of Biological Sciences,Bio-Mega Re-search Division,Boehringer Ingelheim(Canada)Ltd.,Laval,Que´bec H7S2G5,Canada.§Supported by a scholarship from Le Fonds de la recherche en sante´du Que´bec.To whom correspondence should be addressed:Institut de recherches cliniques de Montre´al,110Pine Ave.W.,Montre´al,Que´bec H2W1R7,Canada.Tel.:514-987-5770;Fax:514-987-5764;E-mail: raymonm@ircm.qc.ca.1The abbreviations used are:MDR,multidrug resistance;Pgp,P-glycoprotein;3-MC,3-methylcholanthrene;B(a)P,benzo(a)pyrene; TCDD,2,3,7,8-tetrachlorodibenzo-p-dioxin;DN,daunorubicin;CAT, chloramphenicol acetyl transferase;AhR,aromatic hydrocarbon recep-tor;Arnt,AhR nuclear translocator;EMSA,electrophoretic mobility shift assay;DME,drug metabolizing enzymes;PAH polycyclic aromatic hydrocarbon;XRE,xenobiotic response element;bp,base pair(s);kb, kilobase pair(s).T HE J OURNAL OF B IOLOGICAL C HEMISTRY Vol.276,No.7,Issue of February16,pp.4819–4827,2001©2001by The American Society for Biochemistry and Molecular Biology,Inc.Printed in U.S.A.This paper is available on line at 4819 at ZHEJIANG UNIVERSITY, on November 21, Downloaded fromdrocarbon(PAH)compounds,including3-methylcholanthrene (3-MC),and that this increased expression occurs at the tran-scriptional level(9–11).However,the precise molecular mech-anisms involved in mdr1b regulation in response to3-MC are still unknown.PAHs are carcinogenic compounds arising from the incom-plete combustion of organic matter and are widespread in the environment,including tobacco smoke and tar.PAHs such as 3-MC and benzo(a)pyrene(B(a)P)as well as halogenated aro-matic hydrocarbons such as2,3,7,8-tetrachlorodibenzo-p-di-oxin(TCDD)are specific inducers of genes coding for drug-metabolizing enzymes(DME),including cyp1a1and cyp1a2, that code for cytochromes P450involved in metabolic oxidation (12).PAHs and TCDD bind in the cytoplasm to the aromatic hydrocarbon receptor(AhR),a member of the bHLH-PAS(basic helix-loop-helix Per-Arnt-Sim)family of transcription factors (12,13).The ligand-bound AhR translocates to the nucleus, where it binds as a heterodimer with the AhR nuclear trans-locator(Arnt;another bHLH-PAS protein)to specific cis-acting regulatory DNA sequences located in the promoter of its tar-gets(known as AH-,dioxin-,or xenobiotic-responsive elements (or AHRE,DRE,or XRE,respectively))to enhance their tran-scription(12,13).Given that mdr1b expression is increased in liver cells in response to treatment with various PAHs,it was postulated that mdr1b may be under the control of the AhR(9). However,studies failing to show mdr1induction in the liver of mice treated with TCDD,one of the most potent agonists of the AhR,suggested that mdr1expression was not regulated by AhR(14).The involvement of AhR in the regulation of mdr1 has so far remained controversial.The mouse hepatoma cell lines Hepa-1c1c7(wild type), TAOc1BP r c1(AhR-defective),and BP r c1(Arnt-defective)con-stitute a powerful experimental system to investigate the tran-scriptional regulation of different AhR⅐Arnt targets in response to xenobiotics(12).The two mutant cell lines were derived as B(a)P-resistant variants of Hepa-1c1c7and were identified based on their inability to induce aryl hydrocarbon hydroxylase activity in response to TCDD treatment(15).TAOc1BP r c1cells have a decreased level of AhR(ϳ10%of wild-type cells)and therefore decreased induction of the cyp1a1promoter and lower aryl hydrocarbon hydroxylase activity in response to TCDD and other AhR ligands(15–18).BP r c1cells have a nor-mal cytosolic AhR,which fails to accumulate in the nucleus because of a defective Arnt(15).They have virtually no basal or inducible levels of cyp1a1expression and aryl hydrocarbon hydroxylase activity(15–17).In the present report,we have used this panel of cell lines to investigate the transcriptional regulation of the murine mdr1 gene by3-MC and other xenobiotic compounds.Our results demonstrate that mdr1is transcriptionally induced by3-MC and B(a)P and that this induction is mediated by p53but also requires AhR⅐Arnt.A model for the AhR⅐Arnt-and p53-medi-ated transactivation of mdr1in response to genotoxic stress is proposed.EXPERIMENTAL PROCEDURESCell Culture—Wild-type Hepa-1c1c7and Hepa1–6,AhR-defective TAOc1BP r c1,and Arnt-defective BP r c1cells were obtained from the American Type Culture Collection(ATCC;Manassas,VA)and main-tained in culture under the conditions recommended by the ATCC. Chinese hamster ovary LR73cell lines stably transfected with plasmid constructs carrying full-length cDNAs for the mouse mdr1,mdr2,or mdr3genes(LR73mdr1,LR73mdr2,and LR73mdr3,respectively;a gift from Dr.Philippe Gros,McGill University,Montre´al,Canada)were grown as described elsewhere(19,20).For inductions,cells atϳ50% confluence were exposed to different concentrations of xenobiotics for various periods of time(the exact conditions for each experiment are indicated in the figure legends).3-MC,B(a)P,and daunorubicin were obtained from Sigma,and TCDD was obtained from the Centre d’expertise en analyze environnementale du Que´bec(Laval,Canada).Stock solutions of3-MC(5m M)and B(a)P(25m M)were prepared in Me2SO,and the stock solutions of daunorubicin(1mg/ml)were pre-pared in water.TCDD was obtained in n-nonane at a concentration of 50g/ml and was stored at room temperature.Stock solutions of3-MC, B(a)P,and daunorubicin were stored atϪ80°C.RNA Preparation—Total RNA was prepared from3-MC-treated and untreated hepatocytes as well as from the LR73mdr1,LR73mdr2,and LR73mdr3cell lines by homogenizing the cells in a solution containing guanidium hydrochloride(6M)followed by sequential ethanol precipi-tation,as described previously(21).RNase Protection Assay—The plasmid constructed to detect the mdr1 RNA consisted of a165-bp Bam HI fragment isolated from the mdr1 cDNA(positions1926–2090relative to the ATG initiation codon(22)), blunt-ended with T4DNA polymerase,and cloned into plasmid pGEM-7Z(Promega,Madison,WI)at the Sma I site,giving plasmid pmdr1-G7.This plasmid was linearized with Eco RI and used as a template to synthesize an antisense mdr1probe using SP6RNA polym-erase(Amersham Pharmacia Biotech).The pKX10–3Z plasmid consist-ing of an Xba I–Kpn I mouse-actin cDNA fragment(positions724–969 in the-actin cDNA)cloned into pGEM-3Z at the Xba I and Kpn I sites (kindly provided by Dr.Rashmi Kothary,Institut du cancer de Mon-tre´al,Montre´al,Canada)was used to generate a control actin probe. pKX10–3Z was linearized with Xba I and used to synthesize an anti-sense actin RNA probe with T7RNA polymerase.The riboprobes were synthesized in the presence of[␣-32P]UTP,and the RNase protection assay was performed according to standard protocols(23).Nuclear Run-on Transcription Assay—The run-on experiment was performed essentially as described by Fisher et al.(24).Nuclei wereisolated from Hepa-1c1c7cells treated with Me2SO or with3-MC(5M) for48h and were used to label nascent RNAs with[␣-32P]UTP.Plas-mids pVT101-U/mdr1,carrying the full-length mouse mdr1cDNA(25); pmP1450–3Ј,carrying a1.2-kb Pst I cDNA fragment overlapping part of the mouse cyp1a1cDNA(26)(obtained from the ATCC);and pKX10–3Z were linearized with Stu I,Bam HI,and Xba I,respectively.The linear-ized plasmids were denatured,immobilized in duplicate onto a nylon membrane,and hybridized with the[␣-32P]UTP-labeled RNAs for48h at65°C.The membranes were washed and exposed for7days with two intensifying screens.Slot Blot Analyses—Slot blotting was performed as previously de-scribed(21).RNA samples(10g)were denatured in7ϫSSC-7.5% formaldehyde for15min at65°C and applied to a nylon membrane (Zeta-Probe).Detection of specific RNAs was performed by hybridiza-tion at65°C in0.5M NaPO4,pH7.2,1m M EDTA,7%SDS,1%bovine serum albumin,and100g/ml salmon sperm DNA with32P-labeled DNA probes.The mdr1probe was a4.2-kb Sph I–Eco RI fragment over-lapping the full-length mouse mdr1cDNA,isolated from plasmid pGEM7/mdr1(a gift from Dr.Philippe Gros,McGill University,Mon-tre´al);the cyp1a1probe was a 1.2-kb Pst I fragment isolated from plasmid pmP1450–3Ј;and the actin probe was a245-bp Xba I–Kpn I fragment isolated from pKX10–3Z.The membranes were washed twiceat65°C with a solution containing40m M NaPO4,pH7.2,5%SDS,1 m M EDTA,0.5%bovine serum albumin and twice with a solutioncontaining40m M NaPO4,pH7.2,5%SDS,and1m M EDTA before autoradiography.Chloramphenicol Acetyl Transferase(CAT)Expression Plasmids—Plasmid pMcat5.9consists of a482-bp DNA fragment containing the dioxin-responsive elements of the cyp1a1gene cloned upstream of the mouse mammary tumor virus promoter and the CAT gene(24)(kindly provided by Dr.Allan Okey,University of Toronto).Plasmids pmdr1, p-452,p-245,p-141,and p-93(previously referred to as pSacICAT, pExo6CAT,pExo2CAT,pExo1CAT,and pAluCAT,respectively)have been described elsewhere(27).The mdr1promoter sequence in these constructs ends at positionϩ84with respect to the transcription start site(27).To produce the p53mutant constructs,pM1and pM2,plasmid pSBM13was used.This plasmid consists of a1.2-kb Sac I–Hin dIII mdr1 promoter fragment(positionsϪ1165toϩ84)cloned into M13mp18. Single-stranded DNA was prepared from pSBM13and used as a tem-plate to perform site-directed mutagenesis of the p53binding site,using the mutant oligonucleotides M15Ј-TACCTGAA T AC A TAAAGACA and M25Ј-CGTAAAGA T AA A TCTATGTA(the base changes are shown in boldface type).The resulting M1and M2mdr1promoter fragments were then excised from pSBM13with Sac I and Hin dIII,blunt-ended with T4DNA polymerase,and cloned into plasmid pCAT at the Hin dIII site also blunt-ended with T4DNA polymerase,yielding plasmids pM1 and pM2.The presence of the mutations in the resulting constructs was confirmed by DNA sequencing.Transient Transfections and CAT Assays—Cells were plated at aInduction of the Mouse mdr1Gene by PAHs4820at ZHEJIANG UNIVERSITY, on November 21, Downloaded fromdensity of 8ϫ105/60-mm plate and transfected on the following day with 10g of plasmid DNA,using a standard calcium phosphate pre-cipitation method (28).After incubation with the DNA precipitate for 16h,the cells were washed twice with phosphate-buffered saline and supplied with fresh medium containing the different xenobiotics.After 48h,the cells were collected.Cell extracts were prepared,and protein concentrations were determined by the Bradford method (29).CAT activities were assayed by standard protocols as described previously,using 2g of proteins (27).Preparation of Nuclear Extracts—Nuclear extracts were prepared according to Schreiber et al .(30),with some modifications.Cells were harvested in cold phosphate-buffered saline,0.6m M EDTA and col-lected by centrifugation.The cell pellets were resuspended in 400l of ice-cold buffer A (10m M Tris,pH 8.0,10m M KCl,0.1m M EDTA,0.1m M EGTA,1m M dithiothreitol)containing 0.5m M phenylmethylsulfonyl fluoride,10g/ml aprotinin,1g/ml pepstatin,and 5g/ml leupeptin and swelled on ice for 15min.Subsequently,25l of 10%Nonidet P-40were added,and the tubes were vortexed vigorously.The nuclear pellets were collected by centrifugation and resuspended in 100l of cold buffer C (20m M Tris,pH 8.0,400m M NaCl,1m M EDTA,1m M EGTA,1m M dithiothreitol)in the presence of protease inhibitors.The suspen-sions were shaken vigorously at 4°C for 1h and centrifuged for 15min at 4°C,and the supernatants were frozen in aliquots at Ϫ80°C.Proteinconcentrations were determined by the Bradford method (29).ElectrophoreticMobility Shift Assay—Oligonucleotides overlapping the potential p53binding site in the mdr1promoter (5Ј-GAACACGTA-AAGACAAGTCTAT)and the p53consensus sequence in the p21waf1/cip1promoter (5Ј-GAACATGTCCCAACATGTTGAG)(31)were end-labeled with ␥-32P using T4polynucleotide kinase and annealed to their respec-tive in a M M 2.5m M dithiothreitol,4%Ficoll,1g of poly(dI-dC),and 20,000cpm of radiolabeled probe.The binding reactions were carried out at room temperature for 15min.Where needed,1g of the monoclonal anti-p53antibody pAb421(32)(Calbiochem)or of the polyclonal anti-Jun or anti-Skn-1antibodies (Santa Cruz Biotechnology,Inc.,Santa Cruz,CA)was added,and the incubation was continued for an additional 15min.The complexes were separated on 5%nondenaturing polyacrylamide gels in 1ϫTBE (90m M Tris,65m M boric acid,2.5m M EDTA,pH 8.0)at 200V.The gels were exposed to XAR films (Eastman Kodak Co.)for 16h with two intensifying screens at Ϫ80°C.Western Blotting—Total proteins from 3-MC-or Me 2SO-treated Hepa-1c1c7and BP r c1cells were extracted in ice-cold buffer (10m M Tris-HCl,pH 8.0,150m M NaCl,1m M EDTA,1%Nonidet P-40,and 1%sodium deoxycholate)containing 10g/ml leupeptin,10g/ml aproti-nin,1M sodium orthovanadate,and 1m M phenylmethylsulfonyl flu-oride.Total proteins (75g/sample)or nuclear extracts (30g/sample)were separated by SDS-polyacrylamide gel electrophoresis on a 10%acrylamide gel,transferred to a nitrocellulose membrane,and analyzed with the monoclonal anti-p53antibody pAb421(32)(Calbiochem)at a concentration of 5g/ml.Immune complexes were revealed by incuba-tion with a goat anti-mouse IgG antibody coupled to alkaline phospha-tase (Bio-Rad)and developed with 5-bromo-4-chloro-3-indolylphosphate p -toluidine salt and nitro blue tetrazolium chloride substrates as rec-ommended by the manufacturer (Life Technologies,Inc.).RESULTSTranscriptional Induction of the Mouse mdr1Gene by 3-MC in Hepatoma Cells—We have used an RNase protection assay to study the expression of mdr1in the hepatoma cell line Hepa-1c1c7upon exposure to 3-MC (Fig.1).An mdr1-specific riboprobe was prepared by cloning into pGEM7-Zf a mouse mdr1cDNA fragment overlapping the linker region of the protein,this domain displaying the lowest sequence homology among the three mouse mdr cDNAs (21).When tested with RNA prepared from LR73stable transfectants expressing each of the three mouse mdr cDNAs,the mdr1riboprobe was found to recognize the mdr1RNA but not the mdr2or mdr3RNA,thus confirming its specificity (Fig.1,top right ).The mdr1probe was then used with RNA from Hepa-1c1c7cells treated or not with 3-MC (Fig.1,top left ).This experiment showed that the amount of mdr1RNA detected is very low in untreated cells but is strongly increased in 3-MC-treated cells,demonstrating that expression of the mouse mdr1gene is induced by 3-MCtreatment.The use of an actin probe confirmed that equal quantities of RNA were used in the assay (Fig.1,bottom ).A similar experiment performed with mdr2-and mdr3-specific riboprobes showed that the expression of these genes is not induced under such conditions,demonstrating that the induc-tion of mdr1expression by 3-MC is isoform-specific (data not shown).A nuclear run-on experiment was performed to determine whether mdr1induction by 3-MC occurs at the transcriptional level (Fig.2).In addition to the mouse mdr1cDNA,cDNAs for the mouse cyp1a1gene (known to be transcriptionally regu-lated by 3-MC (12))and for the actin gene were also included as positive and negative controls,respectively.The data in Fig.2show that 3-MC induces an increase in the rate of mdr1mRNA synthesis,indicating that 3-MC acts at the transcriptional level to induce mdr1gene expression in Hepa-1c1c7cells.AhR ⅐Arnt-dependent Induction of mdr1Expression by 3-MC—To determine whether the increase in mdr1expression in response to 3-MC exposure is AhR ⅐Arnt-mediated,we ana-lyzed the mdr1RNA levels upon 3-MC treatment in two wild-type hepatoma cell lines Hepa-1c1c7and Hepa 1–6and in two variant cell lines derived from Hepa-1c1c7,TAOc1BP r c1(AhR-defective)and BP r c1(Arnt-defective)(15)(Fig.3).As controls,we also analyzed the level of cyp1a1and actin expression under the same conditions (Fig.3,middle and right ,respectively).This experiment showed that mdr1is expressed at low levels in the four cell lines in the absence of 3-MC induction (Fig.3,left panel ).Upon 3-MC treatment,the expression of mdr1is in-duced in the two wild-type hepatoma cell lines (by ϳ5-fold),this induction being completely abrogated in the AhR-defective or in the Arnt-defective variants (Fig.3,left panel ).The actin control probe confirmed that equal amounts of RNA had been applied to the membrane (Fig.3,right panel ).These data clearly demonstrate that the induction of mdr1in response to 3-MC requires an intact AhR ⅐Arnt complex,like cyp1a1(Fig.3,middle )(12).The Mouse mdr1Promoter Confers 3-MC-regulated Expres-sion in an AhR ⅐Arnt-dependent Manner—To determine if reg-ulatory sequences responsible for mdr1induction by 3-MC are present in the promoter region of the gene,plasmid pmdr1,consisting of a 1.2-kb Sac I–Hin dIII DNA fragment overlapping the mdr1promoter region (positions Ϫ1165to ϩ84with respect to the transcription start site (27))fused to the CAT reporter gene,was analyzed in transient transfection experiments.Plasmid pMcat5.9,which consists of a 482-bp fragment derived from the cyp1a1promoter fused to the mouse mammary tumorF IG .1.Increased mdr1expression in Hepa-1c1c7upon 3-MC treatment.The expression of mdr1was analyzed by RNase protection assay.Total RNAs (45g)from Hepa-1c1c7cells treated with 5M 3-MC (ϩMC )or with Me 2SO (ϪMC )for 56h and from the control cell lines LR73/mdr1,LR73/mdr2,and LR73/mdr3were analyzed with an mdr1riboprobe,which protects a 169-nt fragment within the mdr1transcript,or with a -actin riboprobe,which protects a 245-nt actin transcript fragment.Autoradiography was for 15h with two intensify-ing screens (mdr1)or for 5h without intensifying screens (actin ).Induction of the Mouse mdr1Gene by PAHs4821at ZHEJIANG UNIVERSITY, on November 21, 2012 Downloaded fromvirus promoter and to the CAT gene (24),as well as the empty pCAT vector were also included as positive and negative con-trols,respectively.The three plasmids were transiently trans-fected into Hepa-1c1c7and BP r c1cells.The cells were treated with 3-MC or with Me 2SO for 48h,and the cellular extracts were prepared and assayed for CAT activity.This experiment showed that the mdr1promoter is transcriptionally active in Hepa-1c1c7cells and BP r c1cells,since it can drive the expres-sion of the CAT gene in both cell lines,albeit at low levels (Fig.4).This result is consistent with the basal level of expression of mdr1detected by slot blot analysis in these cells (Fig.3).3-MC treatment of the Hepa-1c1c7cells transfected with pmdr1re-sulted in a 10-fold induction in CAT activity as compared with untreated cells,reaching levels of CAT activity similar to those detected in the Hepa-1c1c7pMcat5.9transfectants upon 3-MC treatment.However,this induction was completely abrogated in BP r c1cells (Fig.4),consistent with the lack of mdr1induc-tion at the RNA level observed in the slot blot assay (Fig.3).Similar results were obtained upon transfection in TAOc1BP r c1cells (data not shown).These results,showing that the mdr1promoter is able to activate the expression of the reporter gene in response to 3-MC in Hepa-1c1c7but not in BP r c1and TAOc1BP r c1cells,demonstrate that (i)the mdr1promoter is able to confer 3-MC-mediated transcriptional acti-vation;(ii)this activation requires a functional AhR ⅐Arnt com-plex;and (iii)the sequences mediating this induction are lo-cated between positions Ϫ1165and ϩ84in the mdr1promoter.Two Putative XREs Located in the mdr1Promoter Are Dis-pensable for the Induction of mdr1by 3-MC—The AhR ⅐Arnt transcriptional complex binds to a specific DNA sequence,5Ј-(A/T)NGCGTG,known as an XRE to activate transcription (12).XREs render heterologous promoters responsive to xeno-biotics and function in a position-and orientation-independent manner (33,34).Examination of the mdr1promoter sequence indicated the presence of two potential XREs in an inverted orientation in the distal portion of the promoter at positionsϪ1129and Ϫ620(5Ј-CACGCAT and 5Ј-CACGCAA,respective-ly).To identify the cis -acting sequences responsible for the induction of mdr1by 3-MC and to investigate the possible involvement of these putative XREs,we analyzed the tran-scriptional activity of a series of mdr1promoter 5Ј-deletion CAT constructs after transient transfection into Hepa-1c1c7and treatment of the resulting transfectants with 3-MC (Fig.5A ).3-MC treatment of Hepa-1c1c7cells transfected with plas-mids p-452or p-245resulted in a level of CAT induction similar to that observed in cells transfected with plasmid pmdr1car-rying the full-length promoter,indicating that sequences lo-cated within positions Ϫ1165to Ϫ245are dispensable for the induction of mdr1by 3-MC,including the two putative XREs as well as a potential AP-1binding site (5Ј-TGACTCA;positions Ϫ265to Ϫ255(35))(Fig.5,B and C ).However,further deletion of a 104-bp region down to position Ϫ141(p Ϫ141)was found to greatly diminish the induction of CAT activity by 3-MC (Fig.5,B and C ),demonstrating that sequences important for the induction are located between positions Ϫ245and Ϫ141.CAT activity in the absence of 3-MC was reduced in the p Ϫ141transfectants when compared with the p Ϫ245transfectants,indicating that sequences between positions Ϫ245and Ϫ141are also involved in the basal transcriptional activity of the mdr1promoter in hepatoma cells.Finally,we found that alowF IG .2.Nuclear run-on experiment.Nuclei were isolated from Hepa-1c1c7cells treated with 5M 3-MC (ϩMC )or with Me 2SO (ϪMC )for 48h.Nascent RNAs were radiolabeled with [␣-32P]UTP and used to probe duplicate nylon membranes on which denatured cDNAs for mdr1,cyp1a1,and actin had been immobilized.The membranes were washed and exposed for 7days with two intensifyingscreens.F IG .3.AhR ⅐Arnt-dependent induction of mdr1expression by 3-MC.Total RNAs (10g)from wild-type Hepa-1c1c7and Hepa 1–6,AhR-defective TAOc1BP r c1,and Arnt-defective BP r c1cells treated (ϩMC )or not treated (ϪMC )with 3-MC at 5M for 56h were applied onto a nylon membrane.The membrane was hybridized sequentially with an mdr1(left ),a cyp1a1(middle ),and a -actin (right )probe.Autoradiography was for 18h (mdr1and cyp1a1)or for 2h (actin)with two intensifyingscreens.F IG .4.AhR ⅐Arnt-dependent induction of the mdr1promoter by 3-MC.Plasmids pCAT (no promoter),pmdr1(mdr1promoter from position Ϫ1165to ϩ84),and pMcat5.9(pMcat;482-bp fragment from the cyp1a1promoter fused to the mouse mammary tumor virus pro-moter)were transiently transfected into Hepa-1c1c7and BP r c1cells by the calcium phosphate method.The cells were then treated with 3-MC (5M )or Me 2SO for 48h.Total cellular extracts were prepared,and equal quantities of proteins (2g)were assayed for CAT activity.A ,autoradiogram of a representative CAT assay,showing the activity of plasmids pCAT,pmdr1and pMcat in Hepa-1c1c7and BP r c1cells treated (ϩ)or not treated (Ϫ)with 3-MC (MC ).The position of the [14C]chloramphenicol (CM )and of its acetylated products (AcCM )is indicated on the left .B ,quantitative analysis of CAT activities.The percentage of conversion of [14C]chloramphenicol to its acetylated de-rivatives was quantitated by liquid scintillation counting.Open bars ,ϪMC ;filled bars ,ϩMC .The results presented are the averages of three independent transfections performed in duplicate.S.D.values are rep-resented by the bars .Induction of the Mouse mdr1Gene by PAHs4822 at ZHEJIANG UNIVERSITY, on November 21, 2012 Downloaded from。
实验二 RNA提取
实验二小量法提取植物总RNA1 实验目的:通过本实验的学习,了解植物RNA的提取方法,原理;掌握分子生物学实验的基本方法。
2 材料青蒿叶片3 试剂:裂解液RL,去蛋白液RW1,漂洗液RW,RNase-free ddH2O,DnaseI,缓冲液RDD4 仪器设备离心机、离心管、紫外分光光度计、微量移液器、枪头、冰箱、电子天平、高压灭菌锅、一次性手套、电泳仪等。
4.1 实验用的枪头,离心管,PCR管子,以及用于临时盛放Buffer的瓶子均用0.1% DEPC水泡过夜,然后灭菌两次,80℃烘干。
4.2 实验用的镊子,药匙,研钵,高压灭菌(121 ℃,20 min)两次。
5 方法与步骤:5.1 RNA提取1. 匀浆处理:50-100 mg植物叶片在液氮中迅速研磨成粉末,加入550 ul裂解液RL(检查是否已加入巯基乙醇),涡旋剧烈震荡混匀。
2. 9800 rpm离心5 min,吸取450 ul转移至过滤柱CS(黄色)上,CS放在收集管中,12000 rpm离心5分钟,小心吸取收集管中的上清400 ul至RNase-free的离心管中,吸头尽量避免接触收集管中的细胞碎片沉淀。
(注意:由于裂解液较粘稠,所以要剪去部分吸头末端)3. 缓慢加入0.5倍上清体积的无水乙醇,混匀(此时可能会出现沉淀),将得到的溶液和沉淀一起转入吸附柱CR3(无色透明)中,12000 rpm离心1 min,倒掉收集管中的废液,将收集柱CR3放回收集管中。
4. 向吸附柱CR3中加入350 ul 去蛋白液RW1,静置几分钟,12000rpm 离心1 min ,倒掉收集管中的废液,将吸附柱CR3放回收集管中。
5. DNase1工作液的配制:取10ulDNase1储存液放入新的RNase-free 离心管中,加入70ulRDD 溶液,轻柔混匀。
6. 向吸附柱CR3中央加入80 ul 的DNase1工作液,室温静置15分钟。
7. 向吸附柱CR3中加入350 ul 去蛋白液RW1, 12000 rpm 离心1 min ,倒掉收集管中的废液,将吸附柱CR3放回收集管中。
RNA酶保护方法
RNA酶保护法是近十年发展起来的一种全新的mRNA定量分析方法。
其基本原理是将标记的特异RNA探针(32P或生物素)与待测的RNA样品液相杂交,标记的特异RNA探针按碱基互补的原则与目的基因特异性结合,形成双链RNA;未结合的单链RNA经RNA酶A或RNA酶T1消化形成寡核糖核酸,而待测目的基因与特异RNA探针结合后形成双链RNA,免受RNA酶的消化,故该方法命名为RNA酶保护实验.RNA酶保护试验是通过液相杂交的方式,用反义RNA探针与样品杂交,以检测RNA 表达的技术。
一、 RNA酶保护试验的介绍RNA酶保护试验(RNase Protection Assay,RPA) 是通过液相杂交的方式,用反义RNA探针与样品杂交,以检测RNA表达的技术。
与Northern blot和RT-PCR 比较,RPA有以下几个优点:1. 检测灵敏度比Northern杂交高。
由于Northern杂交步骤中转膜和洗膜都将造成样品和探针的损失,使灵敏度下降,而RPA将所有杂交体系进行电泳,故损失小,提高了灵敏度。
2. 由于PCR扩增过程中效率不均一和反应“平台”问题,基于PCR产物量进行分析所得数据的可靠性将下降,而RPA没有扩增过程,因此,分析的数据真实性较高。
3.由于与反义RNA探针杂交的样品RNA仅为该RNA分子的部分片段,因此,部分降解的RNA样品仍可进行分析。
4.步骤较少,耗时短。
与Northern杂交相比,省去了转膜和洗膜的过程。
5. RNA-RNA杂交体稳定性高,无探针自身复性问题,无须封闭。
6. 一个杂交体系中可同时进行多个探针杂交,无竞争性问题。
7. 检测分子长度可以任意设置,灵活性大。
RPA的缺点是需要同位素标记探针。
二、试剂准备1. GACU POOL:取100mM ATP.CTP.GTP各2.78μl.100mM UTP 0.06μl,加DEPC H2O至100μl。
2. 杂交缓冲液:PIPES 0.134g.0.5M EDTA(pH8.0) 20μl.5M NaCl 0.8ml.甲酰胺8ml,加DEPC H2O至10ml。
碧云天RNAeasy动物RNA抽提试剂盒说明书
碧云天生物技术/Beyotime Biotechnology 订货热线: 400-1683301或800-8283301 订货e-mail :****************** 技术咨询: ***************** 网址: 碧云天网站 微信公众号RNAeasy ™动物RNA 抽提试剂盒(离心柱式)(试用装)产品简介:碧云天的离心柱式RNAeasy ™动物RNA 抽提试剂盒(RNAeasy ™ Animal RNA Isolation Kit with Spin Column)是一种基于离心柱法从动物组织或培养的动物细胞中安全、快速、便捷、稳定、高效、高质量地抽提长度大于200个核苷酸(nucleotide, nt)的RNA 的试剂盒。
抽提获得的大于200个核苷酸的RNA(也常被称为总RNA)可以用于各种常规用途。
本试剂盒抽提得到的RNA 可用于反转录、RT-PCR 、qPCR 、Northern 、点杂交(Dot Blot)、纯化mRNA 、体外翻译、RNase protection assay 、cDNA 克隆等下游实验;也可用于基因表达芯片分析(microarray)、高通量测序(high throughput sequencing)等对RNA 质量要求较高的情况。
碧云天的三款离心柱式及Trizol 法RNA 抽提试剂盒的主要特点和差异如下:动物组织或细胞中的RNA 按照长度可以分为长链RNA(long RNA)和小RNA(small RNA),长链RNA 通常大于200nt ,而小RNA 通常小于200nt 。
长链RNA 按照是否编码蛋白或多肽可以分为长链非编码RNA(long noncoding RNA, lncRNA)和mRNA 。
小RNA 主要包括非编码的5.8S rRNA(ribosomal RNA)、5S rRNA 、tRNA(transfer RNA)、microRNA(miRNA)、siRNA(small interfering RNA)、piRNA(Piwi-associated small RNA)、tsRNA(tRNA-derived small RNA)、srRNA(small rDNA-derived RNA)等。
血液标本收集和保存..
血液标本的收集和保存方法说明:一般建议用新鲜的血液标本进行实验。
如果标本已经保存较长时间,请联系康成公司技术部,以确认样本是否适合进行实验。
一、 全血收集请按照实际使用的收集方法,如注射器收集或真空收集管等,参考相应的厂商提供产品说明进行操作。
采集好全血,将采集好的全血转移至单独的冻存管,按照每400~500ul/管分装好。
短期保存,可放入- 20°C 或- 70°C冰箱。
长期保存,请放入液氮。
二、 血浆收集为获得血浆进行实验,应使用抗凝管采集全血,并尽快进行血浆分离:1000g离心10分钟,分离血浆和细胞组分。
将采集好的血浆转移至单独的冻存管,按照每400~500ul/管分装好。
短期保存,可放入- 20°C 或- 70°C冰箱。
长期保存,请放入液氮。
图片来源:Exiqon ‘ Quantification of MicroRNA expression in Blood Plasma/Serum Samples’注意:血浆收集应使用抗凝管,抗凝剂可以用柠檬酸钠或EDTA等,但一定不要使用肝素抗凝,因为肝素对RNA实验有较大影响三、 血清收集为获得血清进行实验,应使用凝血管采集全血,采血后两小时内分离血清。
采血后轻轻倒转采血管混合4~5次,直立置于室温待血液完全凝固(一般约一小时),1000g离心10分钟,分离血清。
将采集好的血清转移至单独的冻存管,按照每400~500ul/管分装好。
短期保存,可放入- 20°C 或- 70°C冰箱。
长期保存,请放入液氮。
四、 血清、血浆和全血样本的保存和运输→ microRNA芯片检测血清、血浆或全血标本约需要1~2ml的量(即每份样品2~4管)。
→在样品保存及转移的过程中,应避免反复冻融样品。
→运输过程必须使用足量干冰保证始终低温。
干冰量至少为8公斤(足量),且运输用厚壁泡沫箱,且需用封箱带密封。
注:保存血清,血浆或者全血所使用的1.5 ml冻存管或离心管,操作中使用的枪头等必须高温灭菌,装好样品后管口需要以封口膜封好。
分子生物学常用实验方法原理介绍
分子生物学常用实验方法原理介绍一、GST pull-down实验基本原理:将靶蛋白-GST融合蛋白亲和固化在谷胱甘肽亲和树脂上,作为与目的蛋白亲和的支撑物,充当一种“诱饵蛋白”,目的蛋白溶液过柱,可从中捕获与之相互作用的“捕获蛋白”(目的蛋白),洗脱结合物后通过SDS-PAGE电泳分析,从而证实两种蛋白间的相互作用或筛选相应的目的蛋白,“诱饵蛋白”和“捕获蛋白”均可通过细胞裂解物、纯化的蛋白、表达系统以及体外转录翻译系统等方法获得。
此方法简单易行,操作方便。
注:GST即谷胱甘肽巯基转移酶(glutathione S-transferase)二、足印法(Footprinting)足印法(Footprinting)是一种用来测定DNA-蛋白质专一性结合的方法,用于检测目的DNA序列与特定蛋白质的结合,也可展示蛋白质因子同特定DNA片段之间的结合。
其原理为:DNA和蛋白质结合后,DNA与蛋白的结合区域不能被DNase(脱氧核糖核酸酶)分解,在对目的DNA 序列进行检测时便出现了一段无DNA序列的空白区(即蛋白质结合区),从而了解与蛋白质结合部位的核苷酸数目及其核苷酸序列。
三、染色质免疫共沉淀技术(Chromatin Immunoprecipitation,ChIP)染色质免疫共沉淀技术(Chromatin Immunoprecipitation,ChIP)是研究体内蛋白质与DNA相互作用的有力工具,利用该技术不仅可以检测体内反式因子与DNA的动态作用,还可以用来研究组蛋白的各种共价修饰以及转录因子与基因表达的关系。
染色质免疫沉淀技术的原理是:在生理状态下把细胞内的DNA与蛋白质交联在一起,通过超声或酶处理将染色质切为小片段后,利用抗原抗体的特异性识别反应,将与目的蛋白相结合的DNA 片段沉淀下来。
染色质免疫沉淀技术一般包括细胞固定,染色质断裂,染色质免疫沉淀,交联反应的逆转,DNA的纯化及鉴定。
四、基因芯片(又称 DNA 芯片、生物芯片)技术基因芯片指将大量探针分子固定于支持物上后与标记的样品分子进行杂交,通过检测每个探针分子的杂交信号强度进而获取样品分子的数量和序列信息。
植物基因组数据挖掘与功能分析
植物基因组数据挖掘与功能分析随着现代基因技术的发展,人们在分子生物学与遗传学的研究中掌握了越来越多的工具和方法。
其中,植物基因组数据挖掘和功能分析已成为近年来研究领域中备受关注的一部分,其先进性和前沿性在一定程度上改变和推进了该领域的发展和研究进程。
一、植物基因组数据获取首先,要进行植物基因组数据的挖掘和功能分析,必须先获取一定数量的数据样本。
数据获取的方式一般分为两种:第一种是建立一个实验室来单独进行实验,第二种是使用已有的公共数据库或者共享数据集。
在传统实验室中,可以通过PCR或者Sanger测序等技术获取植物样品的DNA序列,之后对其进行片段拼接、组装和标注以获得完整的基因组数据。
但时间和成本均较大,而且需要耗费较多的资源。
因此,这种方式通常仅限于小型数据,对于较大的基因组数据并不适用,而且很容易导致研究人员陷入误区和歧义。
对于较大的基因组数据,使用公共数据库或共享数据集则是一个更好的选择。
例如,中国科学院植物研究所发布的植物基因组大数据资源库(Phytozome),经过多年的积累和整合,已经成为国际上最权威的植物基因组资源库之一。
该数据库出版了包含许多物种的高质量参考基因组,这些基因组通过用肮脏的DNA技术组装,以满足科学家各种各样的研究需求。
此外,2003年美国国家卫生研究院(NIH)开展了国际人类基因组计划的同时,还推出了一个公共数据库-基因组数据库(Genome Database),其中包含了包括许多植物物种在内的多种生物物种的全基因组序列和注释信息,极大地方便了人们在相关领域中的研究。
二、植物基因组数据挖掘获取了大量的植物基因组数据,接下来就可以开始进行数据挖掘了。
数据挖掘包括两个主要的方面:一是找到编码基因和非编码RNA,二是确定蛋白质组成以及反应通路和代谢途径。
(一)编码基因和非编码RNA挖掘在植物基因组中的编码基因占据了非常重要的地位,因为它们可以指导着许多重要的生物过程,例如细胞周期、蛋白质合成、细胞信号传导等。
赛默飞世尔-Quant-iT
Quant-iT™ RiboGreen™ RNA Reagent and KitCatalog Numbers R11490, R11491, T11493Pub. No. MAN0002073 Rev. A.0WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear,clothing, and gloves. Safety Data Sheets (SDSs) are available from /support.Product descriptionThe Quant-iT™ RiboGreen™ RNA Reagent is an ultrasensitive fluorescent nucleic acid stain for quantitating RNA in solution. Detecting and quantitating small amounts of RNA is important in many applications including measuring yields of in vitro transcribed RNA and measuring RNA concentrations before performing Northern blot analysis, S1 nuclease assays, RNase protection assays, cDNA library preparation, reverse transcription PCR, and differential display PCR.Figure 1 Dynamic range and sensitivity of the Quant-iT™ RiboGreen™ RNA Assay.For the high-range assay (top panel), the Quant-iT™ RiboGreen™ RNA Reagent was diluted 200‑fold into 10 mM Tris-HCl, 1 mM EDTA, pH 7.5 (TE) and 100 µL of the reagent solution was added to microplate wells containing 100 µL of ribosomal RNA in TE. For the low-range assay (bottom panel), the Quant-iT™ RiboGreen™ RNA Reagent was diluted 2,000‑fold into TE and 100 µL of the reagent solution was added to microplate wells containing 100 µL of ribosomal RNA in TE. Samples were excited at 485 ± 10 nm and the fluorescence emission intensity was measured at 530 ±12.5 nm using a fluorescence microplate reader. Fluorescence emission intensity was then plotted versus RNA concentration.The Quant-iT™ RiboGreen™ RNA Reagent enables quantitation of as little as 1 ng/mL RNA (200 pg RNA in a 200 µL assay volume) with a fluorescence microplate reader using fluorescein excitation and emission wavelengths. The linear range of the Quant-iT™ RiboGreen™ RNAReagent extends over three orders of magnitude in RNA concentration (1 ng/mL to 1 µg/mL) using two dye concentrations (Figure 1). The high-range assay allows quantitation of 20 ng/mL to 1 µg/mL RNA, and the low-range assay allows quantitation of 1 ng/mL to 50 ng/mL RNA. This linearity is maintained in the presence of several compounds commonly found to contaminate nucleic acid preparations, including nucleotides, salts, urea, ethanol, chloroform, detergents, proteins, and agarose. Although the Quant-iT™ RiboGreen™ RNA Reagent also binds to DNA, pretreatment of mixed samples with DNase can be used to generate an RNA-selective assay (see “Eliminate DNA from samples” on page 5).Contents and storage[1]Stand-alone reagent does not include Components B and C.[2]When stored as directed, products are stable for at least 6 months.[3]For long-term storage, the Quant-iT™ RiboGreen™ RNA Reagent can be stored at ≤–20°C[4]For long-term storage, store the rRNA standards at ≤–20°C or –70°C.Required materials not supplied•Nuclease-free pipettors and tips•Nuclease-free water•Microplates for Fluorescence-based Assays, 96-well (Cat. No. M33089)Prepare the assay bufferPrepare the 1X TE working solution by diluting the concentrated buffer (Component B) 20‑fold with nuclease-free water. Prepare nuclease-free water by treating distilled, deionized water with 0.1% diethyl pyrocarbonate (DEPC), incubating for several hours at 37°C, and autoclaving for at least 15 minutes at 15 lbs/sq. inch to sterilize the water and eliminate DEPC.IMPORTANT! TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is used to prepare the Quant-iT™ RiboGreen™ RNA Reagent and for diluting RNA standards and samples. Make sure the TE solution is free of contaminating nucleases and nucleic acids. The 20X TE buffer included in the Quant-iT™ RiboGreen™ RNA Assay Kit is nuclease-free and nucleic acid–free.Prepare the reagentTwo different dye concentrations are required to achieve the full linear dynamic range of the Quant-iT™ RiboGreen™ RNA Assay. Before preparing the working solution of the Quant-iT™ RiboGreen™ RNA Reagent, decide whether you wish to perform the high-range assay (20 ng/mL to 1 µg/mL RNA), low-range assay (1 ng/mL to 50 ng/mL RNA), or both.On the day of the experiment, allow the Quant-iT™ RiboGreen™ RNA Reagent to warm to room temperature before opening the vial,then prepare an aqueous working solution of the Quant-iT™ RiboGreen™ RNA Reagent by diluting the concentrated DMSO stock solution (Component A) into TE, 200‑fold for the high-range assay or 2,000‑fold for the low-range assay. For microplate assays of a total 200 µL assay volume, you need 100 µL of the Quant-iT™ RiboGreen™ RNA Reagent working solution per sample.For example, to prepare enough working solution to assay 100 samples in 200 µL volumes, add 50 µL Quant-iT™ RiboGreen™ RNA Reagent to 9.95 mL TE for the high-range assay or add 5 µL Quant-iT™ RiboGreen™ RNA Reagent to 9.995 mL TE for the low-range assay.Note: Allow the Quant-iT™ RiboGreen™ RNA Reagent to warm to room temperature before opening the vial. Cold DMSO solutions absorb moisture from warmer, room temperature air, resulting in loss of efficacy for the reagent. Always store the DMSO stock solution in thepresence of desiccant when not in use. We recommend preparing the working solution in sterile, disposable polypropylene plasticware rather than glassware, as the reagent may adsorb to glass surfaces. Protect the working solution from light, as the Quant-iT™ RiboGreen™RNA Reagent is susceptible to photodegradation. For best results, use the working solution within a few hours of preparation.Prepare the RNA standard curve1.Prepare a 2 µg/mL solution of RNA in TE using nuclease-free plasticware. Determine the RNA concentration on the basis ofabsorbance at 260 nm (A260) in a cuvette with a 1 cm pathlength; an A260 of 0.05 corresponds to 2 µg/mL RNA.The ribosomal RNA standard (Component C), provided at 100 µg/mL in the Quant-iT™ RiboGreen™ RNA Assay Kit, is diluted 50‑fold in TE to make the 2 µg/mL working solution. For example, 4 µL of the RNA standard mixed with 196 µL of TE is sufficient for the standard curve described in step 2.Note: For a standard curve, we commonly use 16S and 23S ribosomal RNA, although any purified RNA preparation may be used. It is sometimes preferable to prepare the standard curve with RNA similar to the type being assayed. However, most single-stranded RNA molecules yield approximately equivalent signals.Note: The RNA solution used to prepare the standard curve should be treated the same way as the experimental samples and should contain similar levels of contaminants. See “Effects of common contaminants” on page 4 for a list of contaminants tested in the Quant-iT™ RiboGreen™ assay.2.For the high-range standard curve, dilute the 2 µg/mL RNA solution into microplate wells as shown in Table 1. For the low-rangestandard curve, dilute the 2 µg/mL RNA solution 20‑fold into TE to make a 100 ng/mL RNA stock solution, then prepare the dilution series shown in Table 2.Table 1 Protocol for preparing a high-range standard curve.Table 2 Protocol for preparing a low-range standard curve.3.Add 100 µL of the appropriate aqueous working solution of Quant-iT™ RiboGreen™ RNA Reagent (prepared in “Prepare the reagent”on page 2) to each microplate well. Use the high-range working solution for performing the high-range assay, and use the low-range working solution for performing the low-range assay. Mix well and incubate for 2–5 minutes at room temperature, protected from light.4.Measure the sample fluorescence using a fluorescence microplate reader and standard fluorescein wavelengths (excitation∼480 nm, emission ∼520 nm).Note: To ensure that the sample readings remain in the detection range, set the instrument's gain so that the sample containing the highest RNA concentration yields a fluorescence intensity near the microplate reader’s maximum. For optimal detection sensitivity, the instrument gain can be increased for the low-range assay relative to the high-range assay. To minimize photobleaching effects, keep the time for fluorescence measurement constant for all samples.5.Subtract the fluorescence value of the reagent blank from that of each of the samples. Use corrected data to generate a standardcurve of fluorescence versus RNA concentration (see Figure 1).Analyze samples1.Dilute the experimental RNA solution in TE to a final volume of 100 μL in microplate wells.Note: You can alter the amount of sample diluted, provided that the final volume remains 100 μL. High dilutions of the experimental sample may serve to diminish the interfering effect of certain contaminants. However, extremely small sample volumes should be avoided because they are difficult to pipet accurately. In addition, the level of assay contaminants should be kept as uniform as possible throughout an experiment, to minimize sample-to-sample signal variation. For example, if a series of RNA samples contain widely differing salt concentrations, then they cannot be compared to a single standard curve. To avoid this problem, simply adjust the concentration of contaminants to be the same in all samples, if possible (see “Effects of common contaminants” on page 4).2.Add 100 μL of the aqueous working solution of the Quant-iT™ RiboGreen™ RNA Reagent (prepared in “Prepare the reagent” onpage 2) to each sample. Incubate for 2–5 minutes at room temperature, protected from light.3.Measure the fluorescence of the samples using the same instrument parameters used to generate the standard curve (see step 4).To minimize photobleaching effects, keep the time for fluorescence measurement constant for all samples.4.Subtract the fluorescence value of the reagent blank from that of each of the samples. Determine the RNA concentration of thesample from the standard curve generated in “Prepare the RNA standard curve” on page 3.5.The assay can be repeated using a different dilution of the sample to confirm the quantitation results.Effects of common contaminantsThe Quant-iT™RiboGreen™ Assay remains linear in the presence of several compounds that commonly contaminate nucleic acid preparations, although the signal intensity may be affected (Table 3). For the highest accuracy, the standards should be prepared under the same conditions as the experimental samples and contain similar levels of contaminants.Table 3 Effects of common contaminants on the signal intensity of the assay.[1]The compounds were incubated at the indicated concentrations with the Quant-iT™ RiboGreen™ RNA Reagent in the presence of 1.0 mg/mL ribosomal RNA. All samples wereassayed in a final volume of 200 µL in 96‑well microplates using a fluorescence microplate reader. Samples were excited at 485 ± 10 nm and fluorescence intensity was measured at 530 ± 12.5 nm.Eliminate DNA from samplesThe Quant-iT™ RiboGreen™ RNA Reagent also binds to DNA. Fluorescence in samples that is due to the Quant-iT™ RiboGreen™RNA Reagent binding to DNA can be eliminated by pre-treating the sample with RNase-free DNase, ensuring that the entire sample fluorescence is due to dye bound to RNA.1.Prepare 10X DNase digestion buffer: nuclease-free 200 mM Tris-HCl, pH 7.5, containing 100 mM MgCl2 and 20 mM CaCl2.2.Add 0.11 volume of 10X DNase digestion buffer to each DNA-containing sample (for example, to a 9 µL sample, add 1 µL 10Xbuffer).3.Add ∼5 units of RNase-free DNase I per µg of DNA estimated to be in the sample.4.Incubate the sample at 37°C for 90 minutes.5.Dilute the sample at least 10‑fold into TE to diminish effects of the digestion buffer salts on the Quant-iT™ RiboGreen™ assayprocedure.6.Perform the Quant-iT™ RiboGreen™ assay as described (see “Analyze samples” on page 4).Related productsTable 4 Bulk Reagents and KitsTable 5 Microplate Reader AssaysLimited product warrantyLife Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale at /us/en/home/global/terms-and-conditions.html. If you have any questions, please contact Life Technologies at /support.Life Technologies Corporation | 29851 Willow Creek Road | Eugene, Oregon 97402 USAFor descriptions of symbols on product labels or product documents, go to /symbols-definition.The information in this guide is subject to change without notice.DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, THERMO FISHER SCIENTIFIC INC. AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all applicable Limited Use Label Licenses.©2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific, Inc. and its subsidiaries unless otherwise specified./support | /askaquestion。
动植物总RNA提取-Trizol法
动植物总RNA提取-Trizol法Trizol法适用于人类、动物、植物、微生物的组织或培养细菌,样品量从几十毫克至几克。
用Trizol 法提取的总RNA绝无蛋白和DNA污染。
RNA可直接用于Northern斑点分析,斑点杂交,Poly(A)+分离,体外翻译,RNase封阻分析和分子克隆。
1、将组织在液N中磨成粉末后,再以50-100mg组织加入1ml Trizol液研磨,注意样品总体积不能超过所用Trizol体积的10%。
2、研磨液室温放置5分钟,然后以每1mlTrizol液加入0.2ml的比例加入氯仿,盖紧离心管,用手剧烈摇荡离心管15秒。
3、取上层水相于一新的离心管,按每mlTrizol液加0.5ml异丙醇的比例加入异丙醇,室温放置10分钟,12000g离心10分钟。
4、弃去上清液,按每ml Trizol液加入至少1ml的比例加入75%乙醇,涡旋混匀,4℃下7500g离心5分钟。
5、小心弃去上清液,然后室温或真空干燥5-10分钟,注意不要干燥过分,否则会降低RNA的溶解度。
然后将RNA溶于水中,必要时可55℃-60℃水溶10分钟。
RNA可进行mRNA分离,或贮存于70%乙醇并保存于-70℃。
[注意] 1、整个操作要带口罩及一次性手套,并尽可能在低温下操作。
2、加氯仿前的匀浆液可在-70℃保存一个月以上,RNA沉淀在70%乙醇中可在4℃保存一周,-20℃保存一年。
Trizol 是一种新型总RNA 抽提试剂,内含异硫氰酸胍等物质,能迅速破碎细胞,抑制细胞释放出的核酸酶。
TRIzol的主要成分是酚。
主要作用是裂解细胞,使细胞中的蛋白,核酸物质解聚得到释放。
酚虽可有效的变性蛋白质,但是它不能完全抑制RNA酶活性,因此TRIzol中还加入了8-羟基喹啉、异硫氰酸胍、β-巯基乙醇等来抑制内源和外源RNase。
x0.1%的8-羟基喹啉的,与氯仿联合使用可增强对RNase的抑制x异硫氰酸胍属于解偶剂,是一类强力的蛋白质变性剂,可溶解蛋白质,并使蛋白质二级结构消失,细胞结构降解,核蛋白迅速与核酸分离。
Omega公司RNA提取试剂盒说明书
RNA-Solv Reagent®RNA Isolation SolventWARNING: This reagent is toxic if swallowed and in contact with skin. Causes burns. After contact with skin, wash immediately with copious amounts of mild detergent and water. If you feel sick, seek medical advice at once and Quote UN2821.Product No:R6830-00 (5 ml)R6830-01 (100 ml)R6830-02 (200 ml)Storage Conditions:RNA-Solv is stable for at least 24 months®when stored at 2°C-8°C and yields reproducible results.IntroductionRNA-Solv® Reagent is a reagent system for the isolation of total RNA from cells and tissues. The reagent, a single-phase solution consisting of phenol and guanidine isothiocyanate, is modification of the single-step RNA isolation method developed by Chomczynski and Sacchi (1).The sample is homogenized and lysed in RNA-Solv® Reagent which maintains the integrity of the RNA, while disrupting and denaturing endogenous RNases and other cellular components. Extraction of the lysate with chloroform further denatures proteins and separates the mixture into an organic and an aqueous phase. RNA remains exclusively in the aqueous phase, and is subsequently recovered by isopropanol.This method is suitable for small quantities of tissue (<100 mg) and cells (<5 X10), and large quantities of tissue ( up to1 g) and cells 6(<10 ), of human, animal, plant, or bacterial origin. The simplicity 8of the RNA-Solv® Reagent method allows simultaneous processing of a large number of samples. The entire procedure can be completed in one hour. Total RNA prepared in this manner can be used for Northern blot analysis, dot blot hybridization, poly(A) + selection, in vitro translation, RNase protection assay, and molecular cloning. For use in amplification by thermal cycling, treatment of the isolated RNA with RNase-free DNase I is recommended when the two amplimers lie within a single exon.Supplied By User•Chloroform (no isoamyl alcohol added)•Isopropyl alcohol•80% Ethanol (in DEPC-treated water)•RNase-free water•Tabletop centrifuge capable of 12,000 x g at room temperatureGeneral Notes Regarding RNase ContaminationWhenever working with RNA :•Always wear disposable gloves and change gloves frequently.•Use sterile, disposable plasticware and automatic pipettes reserved for RNA work to prevent cross-contamination with RNases.•In the presence of RNA-Solv® Reagent, RNA is protected from RNase contamination. Downstream sample handling requires that nondisposable glassware or plasticware be RNase-free.•Use only DECP-treated buffers. Add DEPC to a final concentration of 0.1%, incubate at 37C for 2 hours, andoautoclave at 121C. Do not add DEPC to Tris buffers. Suchobuffers must be prepared by using DECP-water.PrecautionUse only disposable polypropylene tubes for small samples and glass Corex tubes for larger samples. All tubes must be able to withstand 12,000 x g . Polystyrene tubes may crack with chloroform Before StartingA.Small Samples :To isolate RNA from very small samples (<106 cells or <10 mg tissue) perform homogenization (or lysis) of samples in 0.8 mL of RNA-Solv®, and add 1 mg RNase-free glycogen or yeast tRNA as carrier. This will improve yields obtained with precipitation.B.Difficult Animal Samples: Specimens containing large amounts of proteins, fat, polysaccharides or extracellular material such as muscles, fat tissue, and sperm, will require the following modification. After lysis/homogenization in RNA-Solv® Reagent, centrifuge at 12,000 x g for 10 minutes at room temperature to remove insoluble debris. Often a precipitate forms at the bottom of the tube, but with fatty tissue, a lipid layer will also form above the aqueous phase. The supernatant will contain the RNA and must be carefully transferred to a fresh 1.5 ml microfuge tube before proceeding.C. Interruption the procedure:Following lysis in RNA-Solv®Reagent and before addition of chloroform, samples can be stored at -70C for up to 3 months. In addition, once the RNA is oprecipitated in isopropanol, the pellet may be stored at -20C or -o70C for up to 1 year.oRNA-Solv Protocol for Total RNA Isolation®CAUTION: When working with RNA-Solv® Reagent use gloves and eye protection (safety goggles) and avoid contact with skin or clothing. Work in a chemical fume hood to avoid inhaling vapor. Unless otherwise noted, all steps are to be carried out at room temperature (20C-25C).o o1. Homogenization and lysis of samples: follow either method belowa) Tissue SamplesHomogenize tissue samples in 1 mL of RNA-Solv® Reagent per 50-100 mg of tissue using an appropriate mechanical homogenizer. Alternatively one can pulverize tissue in liquid nitrogen with mortar and pestle and transfer the powder to a clean 1.5 ml microcentrifuge tube. If ceramic mortar and pestle are not available, homogenize the sample in the microfuge tube using a disposable microtube pestle (Eppendorf, Cat No. 0030 120.973; VWR, Cat No. KT 749520-0000). The sample volume should not exceed 10% of the volume of RNA-Solv® Reagent used.b) Cells Grown in SuspensionPellet cells by centrifugation. Lyse cells in RNA-Solv® Reagent by repetitive pipetting. Use 1 mL of the reagent per 5-10 x 10of6 animal, plant or yeast cells, or per 1 x 10 bacterial cells. Washing8cells before addition of RNA-Solv® Reagent should be avoided as this increases the possibility of mRNA degradation and RNase contamination. For plant, fungal, and yeast cells mechanical or enzymatic homogenization may be required. Also, for plant, fungal, and yeast cells, we recommend the use of the E.Z.N.A.® Plant (R6627),Fungal (R6640), and Yeast (R6670) RNA Kits from Omega Bio-tek.c) Cells Grown in MonolayerLyse cells directly in a culture dish by adding 1 mL of RNA-Solv®Reagent to a 3.5 cm diameter dish, and passing the cell lysate several times through a blue pipette tip. The amount of RNA-Solv®Reagent added is based on the area of the culture dish (~1 mL per 10 cm ). An insufficient amount of RNA-Solv® Reagent may result2in contamination of the isolated RNA with DNA. Always use more RNA-Solv® Reagent if in the lysate is too viscous to aspirate with a pipette.2. Add 0.2 mL of chloroform per 1 mL of RNA-Solv® Reagent. Cap sample tubes securely and vortex vigorously for 15 seconds. Incubate on ice for 10 minutes. This step is critical - do not change it.3. Centrifuge the samples at no more than 12,000 x g for 15 minutes 4E C.The mixture separates into a lower phenol-chloroform phase, an interphase, and an upper aqueous phase. RNA remains entirely in the aqueous phase.4. Precipitation of RNA.Transfer no more than 80% of the aqueous phase to a fresh tube, and discard the lower organic phase. Precipitate the RNA from the aqueous phase by adding 500ìl of isopropyl alcohol per 1 mL of RNA-Solv® Reagent used for the initial homogenization. Incubate samples at room temperature 10 minutes and centrifuge at no more than 12,000 x g for 10 minutes also at room temperature.Carbohydrate-rich samples: Plant samples of high polysaccharide content or animal tissues rich in glycosaminoglycans (proteoglycans) require the following modified precipitation method for obtaining pure RNA. Prepare Buffer A ( 1.2 M sodium chloride, 800 mM sodium citrate). Following step 3, add to the aqueous phase 0.3 ml isopropanol followed by 0.3 ml Buffer A per 1 ml RNA Solv ® Reagent used in step 1. Vortex to mix and centrifuge at no more than 12,000 x g for 10 minutes at room temperature. This high salt precipitation will reduce co-purification of complex carbohydrates.5. Wash RNA pellet. Discard the supernatant and wash the RNA pellet once with 1 ml 80% ethanol. Mix the sample by vortexing and centrifuge at no more than 7,500 x g for 5 minutes at room temperature.6.Reconstitute RNA. Carefully aspirate and discard the ethanol and briefly AIR DRY the RNA pellet for 2-5 minutes at room temperature. Do not use centrifugal devices equipped with a vacuum source as over-drying will lead to difficulty in re-dissolving RNA in water. Dissolve RNA in RNase-free water - a 5 minute incubation at 60 °C may be required. RNA can also be reconstituted in 100% formamide (deionized) and stored at -70°C.RNA is now suitable for RNase protection, northern analysis and reverse transcriptase reactions. For isolation of poly(A)+ RNA an additional ethanol precipitation is required. Add 1/8 X volume of RNase-free 3M NaAc, pH 6.0 followed by 2.5 X volume absolute ethanol. Vortex to mix and incubate at room temperature for 5 minutes. Centrifuge at 12,000 x g for 10 min at room temperature and discard the supernatant. Wash the pellet as before and reconstitute in DECP-treated water.Determination of Yield and QualityUV spectrophotometric analysis of the purified RNA is required for obtaining yield. To do so, dilute the RNA in an appropriate volume of TE buffer, pH 8.0 (not water; RNA yields low Abs ratio values if dissolved in acidic buffers) and measure absorbance at 260 nm and at 280 nm. RNA Conc = 40 ìg/ml X Dilution factor X Abs 260 nmTypical Abs 260 nm/ 280 nm ratios of 1.7-1.9 are obtained with the protocol. Yields vary depending of type and amount of starting material, and on condition of storage prior to processing. For assessing the quality of RNA, we recommend you perform denaturing agarose gel electrophoresis to confirm the integrity of purified material. Invariably, the full spectrum of RNAs, including 4S and 5S species are purified with RNA-Solv® Reagent.Expected Yields per 1 mg tissue or 10 cells:6Liver and spleen, 5-10 ìgKidney, 2-5 ìgBrain, 1-2ìgEndothelial cells, 7-12 ìgFibroblasts, 6-8ìgTroubleshooting•Low RNA Yields: Incomplete lysis of samples in RNA Solv Reagent. RNA pellet not completelt dissolved in DEPC-water.pH of diluent used for spectrophotometric analysis is too low.•Degraded RNA: Tissues were not immediately processed or frozen. Inadequate storage of starting material prio to isolation. Inadequate storage of RNA (-5 to -20°C, instead of -60 to -70°C) Trypsin/EDTA was used in dislodging monolayer cells. Buffers or plasticwasre were not RNase-free.Formaldehyde used for denaturing agarose-gel electrophoresis had a pH below 3.0.•Low Abs260/Abs280 ratios: Sample was diluted in water rather than TE. Acidic pH lowers absorbance ratios. Use TE buffer as diluent for readings. Insufficient RNASolv Reagent was used for lysis of sample. Ice incubation in step 2 was not performed. The aqueous phase was contaminated with the phenolic phase.•DNA contamination of RNA: Too little RNASolv Reagent used for sample processing causing inadequate separation of DNA/nucleoprotein complexes from aqueous RNA. The aqueous phase was contaminated with the phenol phase.Technical Support:Omega Bio-tek, USA - call toll-free : 1 888 832 8896References:1. Chomczynski, P., and Sacchi, N. Anal. Biochem. 162, 156 (1987).2. Chomczynski, P. Biotechniques 15, 532 (1993).For laboratory research use only.CAUTION: Not for diagnostic use. The safety and efficacy ofthis product indiagnostic or other clinical uses has not been established.May,1999 (C). All rights reserved by Omega Bio-tek, Inc.RNA-Solv is a registered mark of Omega Bio-tek, Inc.。
环境雌激素及其检测技术
【关键词】环境雌激素环境雌激素类(Environmental estrogens,EEs)内分泌干扰物是指一类具有雌激素样作用的化合物,能模拟或干扰天然激素的生理、生化作用,对生物体产生各种毒效应,包括干扰体内正常内分泌物质的合成、释放、运输、结合、代谢等过程,激活或抑制内分泌系统的调控功能,出现生殖器官异常,雄性雌性化等〔1〕。
目前,EEs分布广泛,种类繁多,并且随着工业化的进程,EEs的污染有进一步扩大的趋势,不仅成为人类健康的潜在威胁因素,也威胁到生物种族的存亡。
各国政府、WHO等组织高度重视,美国国家资源委员会将其列为5个最优先项目之一。
因此,必须建立一套快速简便、科学灵敏的EEs检测筛检方法,并结合其对人体的作用机制,从而对EEs作出科学的、综合的评价,以保护人类健康,预防对人类的危害。
1 EEs及作用机制EEs种类繁多,结构差异较大,对雌激素的干扰作用也有多种不同途径〔2〕。
目前已报道的EEs主要有以下几类:(1)植物雌激素;(2)人工合成药用雌激素;(3)烷基酚类;(4)杀虫剂类;(5)邻苯二四甲酸酯类;(6)多氯联苯与二 英类;(7)金属及非金属类。
研究表明,大多数EEs对机体雌激素、雄激素、甲状腺激素等产生明显的干扰作用,临床上表现为畸胎、生长发育异常、生殖功能障碍、代谢紊乱甚至癌症等;野生动物调查也显示,EEs可引起贝类、鱼、鸟和哺乳动物生育能力下降,引起雄性化、雌性化或双性化,也可使子代存活率下降而可能使某些物种灭绝。
但植物雌激素在一定剂量下对人类健康有利,保护人类免患激素依赖性疾病(如乳腺癌)和某些心血管疾病。
目前,虽然在内分泌及生殖系统的生物学效应具体机制还不十分明确,但主要具备以下4方面的能力;(1)模仿内源性激素;(2)拮抗内源性激素;(3)破坏内源性激素的生成和代谢;(4)破坏激素受体的生成与代谢。
同时,EEs 也能与雌激素受体结合,形成配体-受体复合物,结合到DNA的激素反应元件上,从基因水平调控生理生化过程。
trizol LS 试剂使用中文说明书
TRIzol LS 试剂(ambion)(中文说明书)货号规格室温贮存10296-010 100ml10296-028 200ml产品描述TRIzol LS试剂适用于液体样品,如人、动植物、酵母、细菌或者病毒来源的液体样品,提取高质量的总RNA(DNA和蛋白质也可以)全过程只需1小时。
TRIzol LS试剂里含有酚、异硫氰酸胍和其它成分,由于在摇匀样品过程中能很有效地抑制RNase活性,所以TRIzol LS试剂能维持RNA完整性。
TRIzol LS试剂允许同时处理大量的样品。
TRIzol LS试剂能从一个样品里有序分离提取RNA、DNA和蛋白质。
TRIzol LS试剂均质化样品后,加入氯仿,能看见分层现象,上层是透明的含RNA的水相,中间层,下层是红色的有机相(含有DNA和蛋白质)。
水相RNA用异丙醇能沉淀分离;中间层或者下层中的DNA用乙醇沉淀分离;异丙醇沉淀能使蛋白质从酚-醇相的上清液中沉淀出来。
沉淀出的RNA、DNA 和蛋白质洗脱杂质,重悬后用于下游。
分离的RNA可以用于RT-PCR, Northern Blot analysis, Dot Blot hybridization, poly(A)+ selection, in vitro translation, RNase protection assay, and molecular cloning 分离的DNA可以用于PCR, and Restriction Enzyme digestion, and Southern Blots.分离的蛋白质可以用于Western Blots, recovery of some enzymatic activity, and some immunoprecipitation.注意:TRIzol LS试剂适用于液体样品(如,血液和病毒制品)。
TRIzol LS试剂与TRIzol试剂仅在它们成分的含量上不同,TRIzol LS试剂的浓度更高,因此相对于同个样品时,TRIzol LS试剂需要量更少。
RNA抽提细节技巧小总结
RNA抽提细节技巧小总结对大部分实验人员来说,RNA抽提比基因组DNA抽提要困难得多。
事实上,现有的RNA 抽提方法/试剂,如果用于从培养细胞中抽提RNA,比抽提基因组DNA更方便,成功率也更高。
那为什么同样的方法用于组织RNA的抽提,总会碰到问题呢?组织RNA抽提失败的两大现象是:RNA 降解和组织内杂质的残留。
关于降解问题,首先看一下为什么从培养细胞中抽提RNA不容易降解。
现有的RNA抽提试剂,都含有快速抑制Rnase 的成分。
在培养细胞中加入裂解液,简单的混匀,即可使所有的细胞与裂解液充分混匀,细胞被彻底裂解。
细胞被裂解后,裂解液中的有效成分立即抑制住细胞内的Rnase,所以RNA得以保持完整。
也就是说,培养细胞由于很容易迅速与裂解液充分接触,所以其RNA不容易被降解;反过来讲,组织中的RNA之所以容易被降解,是因为组织中的细胞不容易迅速与裂解液充分接触所致。
因此,假定有一种办法,在抑制RNA活性的同时能使组织变成单个细胞,降解问题也就可以彻底解决了。
液氮碾磨就是最有效的这样一种办法。
但是,液氮碾磨方法非常麻烦,如果碰到样品数比较多的时候更加会有此感觉。
这样就产生了退而求其次的方法:匀浆器。
匀浆器方法没有考虑细胞与裂解液接触前如何抑制Rnase活性这个问题,而是祈祷破碎组织的速度比细胞内的Rnase降解RNA的速度快。
电动匀浆器效果较好,玻璃匀浆器效果较差,但总的来说,匀浆器方法是不能杜绝降解现象的。
因此,如果抽提出现降解,原来用电动匀浆器的,改用液氮碾磨;原来用玻璃匀浆器的,改用电动匀浆器或者直接用液氮碾磨,问题几乎100%能获得解决。
影响后续实验的杂质残留问题,其原因比降解更多样,解决方法相应也不同。
总之,如果出现降解现象或者组织内杂质残留现象,则必须对具体实验材料的抽提方法/试剂进行优化。
优化大可不必使用您的宝贵样品:可以从市场上购买一些鱼/鸡之类的小动物,取相应部分的材料用于RNA抽提,其它部分用于抽提蛋白质——嘴用来碾磨,肠胃用来抽提。
防止RNA酶污染的措施
一、防止RNA酶污染的措施1. 所有的玻璃器皿均应在使用前于180℃的高温下干烤6hr或更长时间。
2. 塑料器皿可用0.1% DEPC水浸泡或用氯仿冲洗(注意:有机玻璃器具因可被氯仿腐蚀,故不能使用)。
3. 有机玻璃的电泳槽等,可先用去污剂洗涤,双蒸水冲洗,乙醇干燥,再浸泡在3% H2O2 室温10min,然后用0.1% DEPC水冲洗,晾干。
4. 配制的溶液应尽可能的用0.1% DEPC,在37℃处理12hr以上。
然后用高压灭菌除去残留的DEPC。
不能高压灭菌的试剂,应当用DEPC处理过的无菌双蒸水配制,然后经0.22μm滤膜过滤除菌。
5. 操作人员戴一次性口罩、帽子、手套,实验过程中手套要勤换。
6. 设置RNA操作专用实验室,所有器械等应为专用。
二、常用的RNA酶抑制剂1. 焦磷酸二乙酯(DEPC):是一种强烈但不彻底的RNA酶抑制剂。
它通过和RNA酶的活性基团组氨酸的咪唑环结合使蛋白质变性,从而抑制酶的活性。
2. 异硫氰酸胍:目前被认为是最有效的RNA酶抑制剂,它在裂解组织的同时也使RNA酶失活。
它既可破坏细胞结构使核酸从核蛋白中解离出来,又对RNA酶有强烈的变性作用。
3. 氧钒核糖核苷复合物:由氧化钒离子和核苷形成的复合物,它和RNA酶结合形成过渡态类物质,几乎能完全抑制RNA酶的活性。
4. RNA酶的蛋白抑制剂(RNasin):从大鼠肝或人胎盘中提取得来的酸性糖蛋白。
RNasin是RNA酶的一种非竞争性抑制剂,可以和多种RNA酶结合,使其失活。
5. 其它:SDS、尿素、硅藻土等对RNA酶也有一定抑制作用。
mRNA的分离与纯化真核细胞的mRNA分子最显著的结构特征是具有5’端帽子结构(m7G)和3’端的Poly(A)尾巴。
绝大多数哺乳类动物细胞mRNA的3’端存在20-30个腺苷酸组成的Poly(A)尾,通常用Poly(A+)表示。
这种结构为真核mRNA的提取,提供了极为方便的选择性标志,寡聚(dT)纤维素或寡聚(U)琼脂糖亲合层析分离纯化mRNA的理论基础就在于此。
重要实验1、RNA酶保护实验RN...
重要实验1、RNA酶保护实验(RNase protection assay):它在许多方面与S1核酸酶分析方法类似。
它是用人工合成的具35S或32P标记的反义RNA探针同目的mRNA杂交,所形成的双链体分子用只切割单链的RNaseA和RNaseT1消化,之后将仍保留着的RNA做大小分部分离,于是被保护的RNA探针便给出了在样品中存在的目的mRNA的大小数值。
此法同样可鉴定样品中mRNA的数量。
2、DNA酶足迹法(DNase footprinting):也叫足迹实验(footprinting assay),是一种用来检测被特定蛋白特异性结合的DNA序列的位置及其核苷酸序列结构特征的实验方法。
基本原理:当DNA分子中的某一区段同特异蛋白结合之后,便会得到保护而免受DNaseⅠ的切割作用,结果不会产生出相应长度的切割分子,于是在凝胶电泳放射自显影图片上便会出现一个空白区,俗称“足迹”。
通过与没有蛋白保护的对照DNA序列比较,便可得知相应于足迹部位的核苷酸序列结构。
3、S1核酸酶定位法(nuclease S1 mapping):用于揭示mRNA序列结构特征的一种技术。
将从一个克隆基因分离的经放射性标记的单链DNA片段同其相应的mRNA退火形成双链分子,然后用S1核酸酶消化此杂合分子上未互补配对的单链序列,再用PAGE及放射自显影方法,检测保留下来的DNA片段的分子大小。
此法可测定克隆基因中的内含子数目及大体位置,mRNA分子的5’端位置及mRNA5’端任何不均一性的程度。
4、染色体步移(chromosome walking):借助反向PCR(inverse PCR)通过使部分序列已知的限制片段自身环化连接,然后在已知序列部位设计一对反向引物,经PCR而使未知序列得到扩增。
重复进行反向PCR,从染色体已知序列出发,逐步扩增出未知序列,称染色体步移。
5、凝胶阻滞实验(gel retardation assay):又叫DNA迁移率变动实验(DNA mobility shift assay),或电泳迁移率实验(electrophoretic mobility shift assay,EMSA),或条带阻滞实验(band retardation assay)。
提取细胞RNA的步骤
提取细胞RNA的步骤:1) 六孔板每孔细胞中加入1ml Trizol,冰上放置5min,枪头吹打。
2) 将各孔裂解液吸到1.5 ml EP管中,加入氯仿0.2ml/管,用力振摇15s。
15-30℃下孵育2-3min,离心(4℃,12,000g,15min)。
3) 离心后液体分为三层(上层-无色水样层为RNA,中层白色为DNA和底层红色为蛋白质),小心吸取上层无色液体移入一新的EP管中。
4) 加入等体积异丙醇,0.4-0.5ml,混匀,15-30℃下孵育10-30min,离心(4℃,12,000g,10min)。
其中如果加入等体积异丙醇后,置于试管架上用PE手套密封后,放于4℃冰箱中,沉淀30min效果更好。
5) 去上清,沉淀加入75%乙醇1ml,漩涡振荡30s,离心(4℃,7,500g,5min)。
6) 小心去上清,管内沉淀在超净台中鼓风静置干燥3-5min。
最好是用枪头吸取上清,尽量除去。
7) 加入20ul DEPC水溶解,分装5ul/管,-70℃冰箱保存。
8) 细胞总RNA的鉴定:0.9-1.2%琼脂糖电泳鉴定细胞总RNA,观察出现条带及各条带亮度。
紫外分光光度计测定:分别测定细胞总RNA在260nm和280nm处的光密度值(OD),并计算RNA 的含量和纯度。
1、实验目的提取人体细胞的总RNA和mRNA。
2、本实验所需试剂1)、CNE-2细胞及培养细胞的一系列条件,2)、PBS缓冲液,TRIZOL试剂,3)、DEPC处理过的水、大、中、小Tip及1.5 ml EP管,4)、新的氯仿、异丙醇和乙醇,5)、mRNA分离试剂盒:Oligotex mRNA Mini Kit,Cat.no.:70022, QIAGEN。
6)、新配的电泳缓冲液,专跑RNA的琼脂糖(Agarose)。
3、实验流程3.1 细胞总RNA的提取1)、6孔板细胞(CNE-2)汇合度为90-100%时,取出无菌室,去其上清,用PBS洗两次后,每孔加TRIZOL试剂(Gibco公司)1 ml,摇匀,无菌罩内消化3-5分钟(观察:液体变粘稠,细胞脱壁)。
RNA抽提注意事项和经验指南-3
RNA抽提注意事项和经验指南-3RNA 抽提的“三大纪律八项注意”纪律一:杜绝外源酶的污染。
注意一:严格戴好口罩,手套。
注意二:实验所涉及的离心管,Tip 头,移液器杆,电泳槽,实验台面等要彻底处理。
注意三:实验所涉及的试剂/溶液,尤其是水,必须确保 RNase-Free。
纪律二:阻止内源酶的活性注意四:选择合适的匀浆方法。
注意五:选择合适的裂解液。
注意六:控制好样品的起始量。
纪律三:明确自己的抽提目的注意七:任何裂解液系统在接近样品最大起始量时,抽提成功率急剧下降。
注意八:RNA 抽提成功的唯一经济的标准是后续实验的一次成功,而不是得率。
Rnase 污染的10大来源1:手指头–手指头是外源酶的第一来源,所以必需戴手套并且频繁更换。
另外,口罩也必需戴,因为呼吸也是一个重要的酶来源。
戴手套口罩的另外的好处是保护实验人员。
2:枪头,离心管,移液器–单纯的灭菌是不能灭活 Rnase 的,所以枪头和离心管要用 DEPC 处理,即使是标明为 DEPC 处理过的。
移液器最好是专用的,用前用75% 的酒精棉球搽拭干净,尤其是杆子;另外,一定不要使用褪头器。
(生物秀实验频道)3:水/缓冲液–一定要确保无 Rnase 污染。
4:实验台面–最起码要用 75% 的酒精棉球搽拭干净。
5:内源 Rnase –所有组织均含内源酶,故组织用液氮速冻是降低降解的最好办法。
液氮保存/碾磨方法的确不方便,但对有一些内源酶含量很高的组织,却是唯一的办法。
6:RNA 样品– RNA 抽提产物可能都会含痕量的 Rnase 污染。
7:质粒抽提–质粒抽提往往用到 Rnase 降解 RNA,残留的 Rnase 要用 Protei nase K 消化,PCI 抽提。
8:RNA 保存–即使低温保存,痕量的 Rnase 亦会导致 RNA 降解。
长期保存 RN A 的最好办法是盐/醇悬液,因为醇在低温时抑制所有的酶活性。
9:阳离子 (Ca, Mg) –在含这些离子时,80C 加热 5 分钟会导致 RNA 被剪切,故如果 RNA 需要被加热,保存液需要含螯合剂 (1mM Sodium Citrate, pH 6.4)。
rna的测定方法
rna的测定方法
RNAs (ribonucleic acids)是一种包含糖基、磷酸和核糖核苷酸的分子,用来储存和传达生物体中的遗传信息。
RNA的测定方法主要包括一种,即RNase Protection Assay (RPA) 。
RPA用于检测RNA信使分子的表达水平,它使用一个能够特异性对RNA结合的引物,然后将一种蛋白酶(如RNaseⅠ)加到它们重叠的位置,使其与RNA结合。
该系统能够将信使RNA切割,以及不能切割的抗体,因此可以确定($[{\rm{mRNA}}]$)的存在。
另一种用于RNA的测定方法,叫做qPCR(实时荧光定量实时聚合酶链反应),它更为精确和敏感。
它是一种反应,用于检测RNA的存在和定量。
它使用特异的引物,使得该引物与信使RNA序列结合,使用一种荧光定量,可以确定($[{\rm{mRNA}}]$)存在的数量。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
RNase Protection Assay发布日期:2006-8-3 热门指数:3608 收藏The ribonuclease protection assay (RPA) is a highly sensitive and specific method for the detection of mRNA species. The assay was made possible by the discovery and characterization of DNA-dependant RNA polymerases from the bacteriophages SP6, T7 and T3, and the elucidation of their cognate promoter sequences. These polymerases are ideal for the synthesis of high-specific-activity RNA probes from DNA templates because these polymerases exhibit a high degree of fidelity for their promoters, polymerize RNA at a very high rate, efficiently transcribe long segments, and do not require high concentrations of rNTPs. Thus a cDNA fragment of interest can be subcloned into a plasmid that contains bacteriophage promoters, and the construct can then be used as a template for synthesis orradiolabeled anti-sense RNA probes.Pharmingen's strategy for the development of multi-probe RPA systems is to generate a series of apoptosis-related gene templates, each of distinct length and each representing a sequence in a distinct mRNA species. The templates are assembled into biologically relevant sets to be used by investigators for the T7 polymerase-directed synthesis of a high-specific-activity, [32P]-labeled antisense RNA probe set. The probe set is hybridized in excess to target RNA in solution after which free probe and other single-stranded RNA are digested with RNases. The remaining "RNase-protected" probes are purified, resolved on denaturing polyacrylamide gel, and quantified by autoradiography or phosphorimaging. The quantity of each mRNA species in the original RNA sample can then be determined based on the intensity of theappropriately-sized, protected probe fragment.Two distinct advantages of the multi-probe RPA approach are its sensitivity and its capacity to simultaneously quantify several mRNA species, in a single sample of total RNA. This allows comparative analysis of different mRNA species within samples and, by incorporating probes for housekeeping gene transcripts, the levels of individual mRNA species can be compared between samples. Moreover,the assay is highly specific and quantitative due to the RNase sensitivity of mismatched base pairs and the use of solution-phase hybridization driven toward completion by excess probe. Lastly, the multi-probe RPA can be preformed on total RNA preparations derived by standard methods from either frozen tissues or cultured cells, withoutfurther purification of poly-A+ RNA.PharMingen's RiboQuant TM Multi-Probe RNase Protection Assay is a complete system available for detecting and quantifying transcripts. This system includes:Multi-Probe Template SetIn Vitro Transcription KitRPA KitIndividual components may be purchased either separately or together as the RPA Starter Package (Cat. No. 45024K). The starter package includes one Template Set, the In VitroTranscription Kit, and the RPA Kit.Standard RPA ProcedureIn all steps of the protocol, standard precautions should be used to avoidRNase contamination and exposure of personnel to radioactivity. Typically,the probe synthesis is performed during the afternoon Day 1, hybridizationsare incubated overnight, and RNase treatments and gel electrophoresis areperformed early on Day 2.Probe Synthesis:1.Bring the [a-32P]UTP, GACU nucleotide pool, DTT, 5X transcriptionbuffer, and RPA template set to RT. For each probe synthesis, addthe following in order to a 1.5 ml Eppendorf tube:1 µl RNasin®1 µl GACU pool2 µl DTT4 µl 5X transcription buffer1 µl RPA Template Set10 µl [a-32P]UTP1 µl T7 RNA polymerase (Keep at -20°C until use, return to -20°Cimmediately).Mix by gentle pipetting or flicking and quick spin in a microfuge.Incubate at 37°C for 1 hour.2.Terminate the reaction by adding 2 µl of DNase. Mix by gentle flickingand quick spin in a microfuge. Incubate at 37°C for 30 minutes.3.Add the following reagents (in order) to each 1.5 ml Eppendorf tube:26 µl 20 mM EDTA25 µl Tris-saturated phenol25 µl chloroform:isoamyl alcohol (50:1)2 µl yeast tRNAMix by vortexing into an emulsion and spin in a microfuge for 5minutes at RT.4.Transfer the upper aqueous phase to a new 1.5 ml Eppendorf tubeand add 50 µl chloroform:isoamyl alcohol (50:1). Mix by vortexing, then spin in a microfuge for 2 minutes at RT.5.Transfer the upper aqueous phase to a new 1.5 ml Eppendorf tubeand add 50 µl 4 M ammonium acetate and 250 µl ice cold 100%ethanol. Invert the tube(s) to mix and incubate for 30 minutes at -70°C. Spin in a microfuge for 15 minutes at 4°C.6.Carefully remove the supernatant and add 100 µl of ice cold 90%ethanol to the pellet. Spin in a microfuge for 5 minutes at 4°C.7.Carefully remove the supernatant and air dry the pellets for 5 to 10minutes (do not dry in a vacuum evaporator centrifuge). Add 50 µl of hybridization buffer and solubilize the pellet by gently vortexing for 20seconds and quick spin on microfuge.8.Quantitate duplicate 1 µl samples in the scintillation counter. Expecta maximum yield of 1-3 x 106 Cherenkov counts / µl (measurement ofcpm / µl without the presence of scintillation fluid) with an acceptable lower limit of 3 x 105 Cherenkov counts / µl. Store the probe at -20°C until needed. Generally, the probe can be used for two successiveovernight hybridizations at most.RNA Preparation & Hybridization:9.For the best results, use procedures that generate total RNA of highquality and purity. RNA should be stored in RNase-free water at-70°C. Add the desired amount of target RNA (generally 1-20 µg) to1.5 ml Eppendorf tubes and include a tube that contains yeast tRNAas a background control. In general, 20-24 total sample tubes are an easily manageable number for each RPA setup. With the Pharmingen control RNA, 2 µl volume (i.e., 2 µg) is recommended.10.If RNA has been stored in water, freeze the samples for 15 minutesat -70°C. Dry completely (~1 hour) in a vacuum evaporator centrifuge (no heat). Likewise, RNA can be precipitated prior to the addition ofhybridization buffer as in Step 5.11.Add 8 µl of hybridization buffer to each sample. Solubilize the RNAby gently vortexing for 3-4 minutes and quick spin in the microfuge.12.Dilute the probe from Step 8 with hybridization buffer to theappropriate concentration: Add 2 µl of diluted probe to each RNAsample and mix by pipetting. Add a drop of mineral oil to each tubeand quick spin in the microfuge.13.Place the samples in a heat block pre-warmed to 90°C. Immediatelyturn the temperature to 56°C (allowing the temperature to ramp down slowly) and incubate for 12-16 hours. Turn the heat block to 37°C for15 minutes prior to the RNase treatments, again allowing thetemperature to ramp down slowly. All incubations may also becarried out in a water bath.RNase Treatments:14.Prepare the RNase cocktail (per 20 samples)2.5 ml RNase buffer6 µl RNase A + T1 mixRemove the RNA samples from the heat block and pipet 100 µl of the RNase cocktail underneath the oil into the aqueous layer (bubble).Spin in microfuge for 10 seconds and incubate for 45 minutes at30°C.15.Before the RNase digestion is completed, prepare the Proteinase Kcocktail (per 20 samples):390 µl Proteinase K buffer30 µl Proteinase K30 µl yeast tRNAMix and add 18 µl aliquots of the cocktail to new Eppendorf tubes.ing a pipettor, extract the RNase digests from underneath the oil(try to avoid the oil) and transfer to the tubes containing the Proteinase K solution. Quick vortex, quick spin in the microfuge, andincubate for 15 minutes at 37°C.17.Add 65 µl Tris-saturated phenol and 65 µl chloroform:isoamyl alcohol(50:1). Vortex into an emulsion and spin in the microfuge for 5minutes at RT.18.Carefully extract the upper aqueous phase (set the pipettor at 120 µland totally avoid the organic interface) and transfer to a new tube.Add 120 µl 4 M ammonium acetate and 650 µl ice cold 100%ethanol. Mix by inverting the tubes and incubate for 30 minutes at -70°C. Spin in the microfuge for 5 minutes at 4°C.19.Carefully remove the supernatant and add 100 µl ice cold 90%ethanol. Spin in the microfuge for 5 minutes at 4°C.20.Carefully remove the supernatant and air dry the pellet (do not dry ina vacuum evaporator centrifuge). Add 5 µl of 1X loading buffer,vortex for 2-3 minutes, and quick spin in the microfuge. Prior toloading the samples on the gel, heat the samples for 3 minutes at 90°C and then place them immediately in an ice bath.Gel Resolution of Protected Probes:21.Clean a set of gel plates (> 40 cm in length) thoroughly with waterfollowed by ethanol. Siliconize the short plate and clean again.Assemble the gel mold (0.4 mm spacers).bine the following to give a final concentration of 5% acrylamide:74.5 ml acrylamide solution (final 19:1 acrylamide/bis):8.85 mls of 40% acrylamide9.31 mls of 2% bis acrylamide7.45 mls of 10x TBE35.82 g of UreaQS to 74.5 ml with dH2O450 µl ammonium persulfate (10%)60 µl TEMEDPour immediately into the gel mold, remove any air bubbles, and add an appropriate comb (e.g., 5 mm well width). Use of a sharks toothcomb is not recommended.23.After polymerization (~1 hour), remove the comb and flush the wellsthoroughly with 0.5X TBE. Place each gel in a vertical rig (use a gelset up that has a heat dispenser) and prerun at 40 watts constantpower for ~ 45 minutes, with 0.5X TBE as the running buffer. Geltemperature should be 50°C.24.Flush the wells again with 0.5X TBE and load the samples (from Step20). Also load a dilution of the probe set in loading buffer (typically1000-2000 cpm/lane) to server as size markers. Run the gel at 50 watts constant power until the leading edge of the Bromophenol Blue(BPB) (front dye) reaches 30 cm.25.Disassemble the gel mold, remove the short plate, and absorb thegel to filter paper. Cover the gel with Saran wrap and layer between two additional pieces of filter paper. Place in the gel dryer vacuum for ~ 1 hour at 80°C. Place the dried gel on film (Kodak X-AR) in a cassette with an intensifying screen and develop at -70°C (Exposure times will vary depending on application). Alternatively, radioactivity can be quantified by phosphorimaging or other equivalentinstruments.26.With the undigested probes as markers, plot a standard curve on asemi-log graph paper, of migration distance versus log nucleotidelength. Use this curve to establish the identity of "RNase-protected"bands in the experimental samples. Note that the probe lengths aregreater than the "protected" fragment lengths, this is due to thepresence of flanking sequences in the probes that are derived from the plasmid and do not hybridize with target mRNA.Technical Tips:Poor probe recoveries.e of [a-32P]UTP that has decayed beyond one half life may lead todecreased probe labeling and increased lane background. Werecommend the use of [a-32P]UTP which does not containcommercial stabilizers.B.Avoid repeated freeze-thaw of the DTT stock solution. Werecommend storing small aliquots at -20°C.C.Make sure that the transcription reagents (nucleotides, DTT, and 5Xtranscription buffer) are at RT prior to adding RPA template.Spermidine present in the transcription buffer can precipitate DNA atlow temperatures.D.Careless removal of ethanol from the precipitated probe can lead tosignificant losses (we have included yeast tRNA as a carrier to facilitate precipitation). If this problem is suspected, recentrifuge theethanol supernatant.E.Check the integrity of the probe set by analyzing it on acrylamide gel.Note: High level of certain mRNA species obscure detection ofother, rarer mRNA species.F.Consult Pharmingen for the availability of RPA template setscustomized to omit probes for the highly expresses transcripts in yourRNA preparations.High levels of breakdown products in the gel lanes.A. A reasonable level of protected probe fragmentation is normalbecause mRNA degradation is a natural occurrence within cells.However, if excessive degradation is observed, check the integrity of your RNA samples by gel electrophoresis.B.Rigorously adhere to the prescribed RNase digestion conditions.These have been carefully optimized for the Pharmingen RPAtemplate sets.e caution when extracting the aqueous phase from thephenol-chloroform extraction (Step 18) because residual RNase may be present in the organic interface. This problem can be remedied by performing a second phenol-chloroform or chloroform-onlyextraction.。